C33(S), a novel PDE9A inhibitor, protects against rat cardiac hypertrophy through upregulating cGMP signaling

Prognostic Implications of Echocardiographically Determined Left Ventricular Mass in the Framingham Heart Study

Daniel Levy, Robert J. Garrison, Daniel D. Savage et al. · New England Journal of Medicine · 1990 · 5.7K citations · Full text

Medicine, Cardiology, Internal Medicine +17

Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure With Preserved Ejection Fraction

Margaret M. Redfield, Horng H. Chen, Barry A. Borlaug et al. · JAMA · 2013 · 1.1K citations

Medicine, Cardiology, Pharmacology +13

Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease

Dong I. Lee, Guangshuo Zhu, Takashi Sasaki et al. · Nature · 2015 · 349 citations · Full text

Life Sciences, Cardiology, Physiology +11

Isolation and Characterization of PDE9A, a Novel Human cGMP-specific Phosphodiesterase

Douglas A. Fisher, James F. Smith, Joann S. Pillar et al. · Journal of Biological Chemistry · 1998 · 342 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +9

Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes

Beate Fiedler, Suzanne M. Lohmann, Albert Smolenski et al. · Proceedings of the National Academy of Sciences · 2002 · 277 citations · Full text

Life Sciences, Cardiology, Physiology +14